Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease

Jie Gao, Bao Ling Adam, Alvin V Terry

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The currently available therapies for Alzheimer's disease (AD) and related forms of dementia are limited by modest efficacy, adverse side effects, and the fact that they do not prevent the relentless progression of the illness. The purpose of the studies described here was to investigate the neuroprotective effects of the nicotine metabolite cotinine as well as a small series of cotinine and nicotine analogs (including stereoisomers) and to compare their effects to the four clinically prescribed AD therapies.

Original languageEnglish (US)
Pages (from-to)1472-1478
Number of pages7
JournalBioorganic and Medicinal Chemistry Letters
Volume24
Issue number6
DOIs
StatePublished - Mar 15 2014

Fingerprint

Cotinine
Neuroprotective Agents
Nicotine
Alzheimer Disease
Stereoisomerism
Metabolites
Dementia
Therapeutics

Keywords

  • Amyloid
  • Dementia
  • Disease modifying
  • Excitotoxicity
  • Glutamate
  • Multi-target-directed ligands
  • Multifunctional compounds
  • Neurodegeneration
  • Neuroprotection
  • Nicotinic

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease. / Gao, Jie; Adam, Bao Ling; Terry, Alvin V.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 24, No. 6, 15.03.2014, p. 1472-1478.

Research output: Contribution to journalArticle

@article{e89ce855fba649f59c66cb5e39b8ed5a,
title = "Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease",
abstract = "The currently available therapies for Alzheimer's disease (AD) and related forms of dementia are limited by modest efficacy, adverse side effects, and the fact that they do not prevent the relentless progression of the illness. The purpose of the studies described here was to investigate the neuroprotective effects of the nicotine metabolite cotinine as well as a small series of cotinine and nicotine analogs (including stereoisomers) and to compare their effects to the four clinically prescribed AD therapies.",
keywords = "Amyloid, Dementia, Disease modifying, Excitotoxicity, Glutamate, Multi-target-directed ligands, Multifunctional compounds, Neurodegeneration, Neuroprotection, Nicotinic",
author = "Jie Gao and Adam, {Bao Ling} and Terry, {Alvin V}",
year = "2014",
month = "3",
day = "15",
doi = "10.1016/j.bmcl.2014.02.008",
language = "English (US)",
volume = "24",
pages = "1472--1478",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease

AU - Gao, Jie

AU - Adam, Bao Ling

AU - Terry, Alvin V

PY - 2014/3/15

Y1 - 2014/3/15

N2 - The currently available therapies for Alzheimer's disease (AD) and related forms of dementia are limited by modest efficacy, adverse side effects, and the fact that they do not prevent the relentless progression of the illness. The purpose of the studies described here was to investigate the neuroprotective effects of the nicotine metabolite cotinine as well as a small series of cotinine and nicotine analogs (including stereoisomers) and to compare their effects to the four clinically prescribed AD therapies.

AB - The currently available therapies for Alzheimer's disease (AD) and related forms of dementia are limited by modest efficacy, adverse side effects, and the fact that they do not prevent the relentless progression of the illness. The purpose of the studies described here was to investigate the neuroprotective effects of the nicotine metabolite cotinine as well as a small series of cotinine and nicotine analogs (including stereoisomers) and to compare their effects to the four clinically prescribed AD therapies.

KW - Amyloid

KW - Dementia

KW - Disease modifying

KW - Excitotoxicity

KW - Glutamate

KW - Multi-target-directed ligands

KW - Multifunctional compounds

KW - Neurodegeneration

KW - Neuroprotection

KW - Nicotinic

UR - http://www.scopus.com/inward/record.url?scp=84895816602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895816602&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2014.02.008

DO - 10.1016/j.bmcl.2014.02.008

M3 - Article

VL - 24

SP - 1472

EP - 1478

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 6

ER -